|
|
Post by lakers on Nov 21, 2017 22:13:27 GMT -5
|
|
|
|
Post by rockstarrick on Nov 21, 2017 23:05:41 GMT -5
And not a word about Afrezza.
Thank GAWD we are starting the Marketing Campaign.
This is a cut-throat business.
|
|
|
|
Post by joeypotsandpans on Nov 21, 2017 23:20:54 GMT -5
What's amazing about this is that Bruce Bode is Sam Finta's doc see Sam's blog portion referencing Bode, here is the link for the entire blog piece but below is the section with Dr. Bode regarding the "real deal -Afrezza": afrezzauser.com/afrezza-confirmed-by-doctor-as-real-deal/From: “Bruce Bode” Date: Mar 12, 2015 12:22 AM Subject: Re: Afrezza To: “Kyle Daniels” (and several others) Glucose and lipotoxicity occurs regardless of the type of diabetes; glucose does not know if the patient is type 1 or type 2. High Glucose and High FFA and other factors impair insulin action as well as insulin release. We see this phenomena all the time in new onset type 1 diabetes; They go into a honeymoon upon treatment of insulin due to breaking both glucose and lipo toxicity. This may last months or longer. Sam’s A1c was above 10% with marked variability with now a mean glucose of 95 mg/dl with a SD <35; Amazing; his C-peptide was < 0.3 checked last month. Afrezza is the real deal for individuals like Sam who failed on MDI and are motivated to improve their control. Afrezza allows him to be aggressive with pre meal insulin with low risk of hypoglycemia. Bruce Bruce W. Bode, MD FACE Now some 2 1/2 yrs. later he's talking about Fiasp which Sam says isn't even in the same league.... |
|
|
|
Post by mnholdem on Nov 21, 2017 23:30:04 GMT -5
...but whose makers have deep pockets to pay for physician reviews.  |
|
|
|
Post by joeypotsandpans on Nov 22, 2017 0:06:57 GMT -5
...but whose makers have deep pockets to pay for physician reviews. same one that has the deep pockets to help UHC continue to beat earnings quarter after quarter at the expense of their insured ....take you pick on which one you want to read: www.google.com/search?q=uhc+quarterly+earnings&rlz=1C1VFKB_enUS603US605&oq=uhc+quarter&aqs=chrome.0.0j69i57j0.9795j0j7&sourceid=chrome&ie=UTF-8 ....thus the circle jerk from them that was referred to in the interview. Where's Bode's integrity, has to be very disappointing to Sam of the possibility that his doc got bought like that.....it seems rather obvious otherwise he would have absolutely had to acknowledge the superior option of which he's well too familiar with as in the REAL DEAL as opposed to the imposter. SMH so sad, need more like Mike in society, as has been said....TG for Mike. |
|
|
|
Post by mnholdem on Nov 22, 2017 6:29:38 GMT -5
Peer reviews of trial data is important and I don't have a problem with researchers being compensated for their time. Dr. Bode reviews diabetes treatments from various pharma companies and doesn't appear to play favorites, IMO.
|
|
|
|
Post by sportsrancho on Nov 22, 2017 7:45:13 GMT -5
And not a word about Afrezza. Thank GAWD we are starting the Marketing Campaign. This is a cut-throat business. “The intention of rapid-acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, ... We will piggyback on this:-) |
|
|
|
Post by goyocafe on Nov 22, 2017 9:41:35 GMT -5
|
|
|
|
Post by agedhippie on Nov 22, 2017 9:42:10 GMT -5
... Now some 2 1/2 yrs. later he's talking about Fiasp which Sam says isn't even in the same league.... Fiasp is not in the same league, but it is pumpable and that makes it a big deal both for existing pump users who get a faster insulin simply by loading a different insulin, and for a closed loop AP. Faster insulin with no life style change - that's a winner. Insurance roll out will be relatively easy. It costs the same as Novolog so any PBM that allows Novolog will allow Fiasp as it doesn't impact their rebates since they are both Novo Nordisk insulins. |
|
|
|
Post by robbmo on Nov 22, 2017 10:36:17 GMT -5
I like this part:
Chantal Mathieu, PhD, professor of medicine and director of biomedical sciences, University of Leuven, Belgium, and colleagues recently reviewed the relative advantages of the faster insulin analog, acknowledging that some observers are “underwhelmed” by the gain of just a few minutes in onset.3
|
|
|
|
Post by babaoriley on Nov 22, 2017 10:46:38 GMT -5
And not a word about Afrezza. Thank GAWD we are starting the Marketing Campaign. This is a cut-throat business. “The intention of rapid-acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, ... We will piggyback on this:-)Sports, you should go into the lemonade business!  |
|
|
|
Post by agedhippie on Nov 22, 2017 11:19:41 GMT -5
I like this part: Chantal Mathieu, PhD, professor of medicine and director of biomedical sciences, University of Leuven, Belgium, and colleagues recently reviewed the relative advantages of the faster insulin analog, acknowledging that some observers are “underwhelmed” by the gain of just a few minutes in onset.3 That's my problem with using Fiasp. I don't see the gain over my existing insulin as big enough for the risk of the incipients they added. The overwhelming likelihood is that it is safe, but why take a chance I don't have to when I can wait. |
|
|
|
Post by uvula on Nov 23, 2017 7:53:59 GMT -5
Excellent point hippie. Mnkd should promote this point. Afrezza is insulin. The other "insulins" are insulin mixed with a bunch of other chemicals.
|
|
